Patents by Inventor Mohammad Tabrizifard

Mohammad Tabrizifard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-COAGULATION FACTOR XI ANTIBODIES
    Publication number: 20230287141
    Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
    Type: Application
    Filed: April 18, 2023
    Publication date: September 14, 2023
    Applicants: Merck Sharp & Dohme LLC, Adimab, LLC
    Inventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz, Vaishnavi Ganti, Mohammad Tabrizifard
  • Anti-coagulation factor XI antibodies
    Patent number: 11661460
    Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: May 30, 2023
    Assignees: Merck Sharp & Dohme LLC, Adimab, LLC
    Inventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Vaishnavi Ganti, Mohammad Tabrizifard, Bianka Prinz
  • ANTI-COAGULATION FACTOR XI ANTIBODIES
    Publication number: 20200317811
    Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
    Type: Application
    Filed: May 1, 2020
    Publication date: October 8, 2020
    Applicants: Merck Sharp & Dohme Corp., Adimab, LLC
    Inventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Vaishnavi Ganti, Mohammad Tabrizifard, Bianka Prinz
  • ANTI-COAGULATION FACTOR XI ANTIBODIES
    Publication number: 20200308302
    Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
    Type: Application
    Filed: May 1, 2020
    Publication date: October 1, 2020
    Applicants: Merck Sharp & Dohme Corp., Adimab, LLC
    Inventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Vaishnavi Ganti, Mohammad Tabrizifard, Bianka Prinz
  • ANTI-COAGULATION FACTOR XI ANTIBODIES
    Publication number: 20200270364
    Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
    Type: Application
    Filed: May 1, 2020
    Publication date: August 27, 2020
    Applicants: Merck Sharp & Dohme Corp., Adimab, LLC
    Inventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Vaishnavi Ganti, Mohammad Tabrizifard, Bianka Prinz
  • ANTI-COAGULATION FACTOR XI ANTIBODIES
    Publication number: 20200255542
    Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
    Type: Application
    Filed: May 1, 2020
    Publication date: August 13, 2020
    Applicants: Merck Sharp & Dohme Corp., Adimab, LLC
    Inventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Vaishnavi Ganti, Mohammad Tabrizifard, Bianka Prinz
  • Anti-coagulation factor XI antibodies
    Patent number: 10584179
    Abstract: Antibodies that bind the apple 2 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa are described.
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: March 10, 2020
    Assignees: Merck Sharp & Dohme Corp., Adimab, LLC
    Inventors: Zhu Chen, Kenneth P. Ellsworth, James A. Milligan, Elizabeth Oldham, Dietmar Seiffert, Vaishnavi Ganti, Mohammad Tabrizifard, Bianka Prinz
  • Anti-coagulation factor XI antibodies
    Patent number: 10053515
    Abstract: Antibodies that bind the apple 2 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa are described.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: August 21, 2018
    Assignees: Merck Sharp & Dohme Corp., Adimab LLC
    Inventors: Zhu Chen, Kenneth P. Ellsworth, James A. Milligan, Elizabeth Oldham, Dietmar Seiffert, Vaishnavi Ganti, Mohammad Tabrizifard, Bianka Prinz
  • ANTI-COAGULATION FACTOR XI ANTIBODIES
    Publication number: 20170355780
    Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
    Type: Application
    Filed: June 12, 2017
    Publication date: December 14, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Vaishnavi Ganti, Mohammad Tabrizifard
  • ANTI-COAGULATION FACTOR XI ANTIBODIES
    Publication number: 20170226225
    Abstract: Antibodies that bind the apple 2 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa are described.
    Type: Application
    Filed: January 19, 2017
    Publication date: August 10, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Zhu Chen, Kenneth P. Ellsworth, James A. Milligan, Elizabeth Oldham, Dietmar Seiffert, Vaishnavi Ganti, Mohammad Tabrizifard